Proleukin® (aldesleukin) treatment should be withheld for failure to maintain organ perfusion as demonstrated by altered mental status, reduced urine output, a fall in the systolic blood pressure ...
Shares of Iovance Biotherapeutics IOVA were up 11.6% on Jan 24 after management announced multiple business, clinical, and regulatory updates. Iovance announced that it has entered into an ...
U.K.-based CRO Clinigen has bought the rights to Novartis’ Proleukin (aldesleukin) outside the U.S. as it looks to boost sales with new dosing and tie-ups with other drugs. Neither company has shown ...
BURTON UPON TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the ...
(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total ...
Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results